期刊文献+

腹腔镜根治术对于14例转移性前列腺癌的围术期效果观察 被引量:6

Perioperative effect of laparoscopic radical resectionof metastatic prostate cancer:a report of 14 cases
暂未订购
导出
摘要 目的探讨腹腔镜根治术对转移性前列腺癌的安全性和疗效。方法对14例确诊骨转移或淋巴结转移的前列腺癌患者实施腹腔镜前列腺癌根治术,观察围术期指标、术后近期并发症、切缘情况、术后前列腺特异抗原(PSA)水平变化及转移灶变化等指标。结果 14例患者均顺利完成腹腔镜根治术,手术时间平均在170min,出血量平均为400mL,直肠损伤7%(1/14),无膀胱输尿管损伤,术后平均住院日为8d,切缘阳性率57%(8/14),严重尿漏7%(1/14),淋巴漏50%(7/14)。术后随访6个月,1个月尿失禁发生率80%,3个月为50%,6个月为0%。术后3月内无内分泌治疗的情况下,PSA水平均较术前降低。结论腹腔镜前列腺根治术切除前列腺原发灶对伴有远处转移的患者是安全可行的,这需要由丰富腔镜经验的泌尿外科医生操作,并且术前需要对手术患者进行充分的筛选。术后近期PSA水平均有不同程度下降。 Objective To investigate the safety and efficacy of radical prostatectomy of metastatic prostate cancer. Methods Radical laparoscopic prostatectomy was performed in 14 confirmed cases of prostate cancer with bone metastasis or lymph node metastasis. The perioperative outcomes, short-term complications, margin status, postoperative changes of PSA level and metastasis were recorded. Results All operations were successful. The mean operation time was 170 min, hemorrhage volume averaged 400 mL, postoperative average hospitalization was 8 days, and positive margin rate was 57 % (8/14). The incidence of rectal injury, severe anastomotic leak and lymph leak was 7% (1/14), 7% (1/14) and 50% (7/14). The incidence of urinary incontinence was 80 %, 50 %, and 0 % 1 month, 3 months and 6 months after surgery. With no hormone deprivation therapy within 3 months, the level of PSA was lower than that before operation. Conclusion Laparoscopic radical prostatectomy is safe and feasible for patients with distant metastasis, which requires experienced urologic surgeons and adequate screening of suitable patients. Postoperative short-term PSA levels decrease in different degrees.
出处 《现代泌尿外科杂志》 CAS 2016年第10期772-775,共4页 Journal of Modern Urology
关键词 转移性前列腺癌 前列腺根治术 腹腔镜 metastatic prostate cancer radical prostatectomy laparoscopy
  • 相关文献

参考文献11

  • 1马春光,叶定伟,李长岭,周芳坚,姚旭东,张世林,戴波,张海梁,朱耀,沈益君.前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J].中华外科杂志,2008,46(12):921-925. 被引量:134
  • 2MELISSA M C, AHMEDIN J, JOANNIE L T,et al. Interna- tional variation in prostate cancer incidence and mortality rates [J]. Eur Urol,2012, 61(6):1079 1092.
  • 3那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2014:528.
  • 4HEIDENREICH EAU guidelines o vanced, relapsing A, BASTIAN P J, BELLMUNT J, et al. n prostate cancer. Part II: Treatment of ad , and castration - resistant prostate cancer [J]. Eur Urol,2014,65(2) :467 -479.
  • 5GRATZKE C, ENGEL J, STIEF CG. Role of radical prostatec- tomy in clinically non-organ-confined prostate cancer[J]. Curr Urol Rep,2014,15(11) :455.
  • 6PRASANNA S, JEFFREY K, CHRISTIAN S,et al. A Multi- institutional analysis of perioperative outcomes in 106 men who underwent radical prostateetomy for distant metastatic prostate cancer at presentation[J]. Eur Uro,2016, 69(5):788-794.
  • 7JAMES ND, SPEARS MR, CLARKE NW, et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAM- PEDE trial (MRC PR08, CRUK/06/019) [J]. Eur Urol,2015, 67(6):1028-1038.
  • 8CULP SH, SCHELLHAMMER PF, WILLIAMS MB. Might men diagnosed with metastatic prostate cancer benefit from de- finitive treatment of the primary tumor? A SEER-based study [J]. Eur Urol,2014,65(6) : 1058-1066.
  • 9HEIDENREICH A, PFISTER D, PORRES D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-con- trol study[J]. J Urol,2015,193(3):832-838.
  • 10TEWARI A, SOORIAKUMARAN P, BLOCH DA, et al. Pos- itive surgical margin and perioperative complication rates of pri- mary surgical treatments for prostate caneer a systematic review and meta-analysis comparing retropubic, laparoscopic, and ro- botic prostatectomy[J]. Eur Urol,2012,62(1) : 1-15.

二级参考文献16

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 4Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 5Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 6Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 7Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 8Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 9Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.
  • 10Darer A,Soret JY, Coblentz Y, et al. The usefulness of prostate- specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol, suppl, 1988, 11 :S53-S57.

共引文献162

同被引文献47

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部